What are the key takeaways from the PsO cohort of the SERENA study?

PsOPsA Hub Steering Committee member Peter Nash, Griffith University, Queensland, AU, spoke with Karl Gaffney, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK, at the American College of Rheumatology (ACR) Convergence 2025, Oct 24–29, 2025, Chicago, US. They discussed findings from the psoriasis (PsO) cohort of the real-life, long-term, observational SERENA (CAIN457A3403) study, evaluating secukinumab in moderate-to-severe plaque PsO, psoriatic arthritis (PsA), and ankylosing spondylitis.¹  

Gaffney highlighted that only 1.7% of patients with plaque PsO at baseline developed PsA over 5 years, regardless of nail involvement, and no predictors of PsA development from PsO were identified.¹ He noted that sub-analyses are planned to assess the risk of PsA development relative to PsO severity.¹